Could a common heart drug help dialysis patients?
NCT ID NCT07417215
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the drug sacubitril/valsartan can improve heart function in people with heart failure who are on chronic hemodialysis. 52 patients were split into two groups: one received the drug, the other standard care. Researchers measured changes in heart ultrasound and blood markers over 2 months to see if the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacubitril/valsartan
What this could lead to
If it works, this could point toward a new treatment option for heart failure in people on dialysis, a group with few effective therapies.
What could go wrong
This is a small, early-phase study with only 52 participants and a short 2-month follow-up. The drug is not yet approved for dialysis patients, and results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Clinical Hospital Mostar
Mostar, 88000, Bosnia and Herzegovina